XRS2 Antibody

What is XRS2 and what is its primary function in cells?

XRS2 is a component of the Mre11/Rad50/Xrs2 (MRX) complex involved in DNA damage repair, DNA damage response, telomere control, and meiotic recombination. In yeast, the XRS2 protein contains multiple functional domains, including a Mre11-binding domain that is essential for MRX complex formation and a Tel1-binding domain involved in telomere maintenance. XRS2 facilitates the proper functioning of DNA repair machinery, particularly in homologous recombination pathways that maintain genomic stability during cell division .

Methodologically, XRS2's functions are typically studied using various genetic and biochemical approaches, including mutations at specific domains, protein interaction studies, and functional assays for DNA repair and recombination.

What are the key applications for XRS2 antibodies in research settings?

XRS2 antibodies are valuable tools that can be used in multiple experimental applications:

• Western blotting (WB): For detecting and quantifying XRS2 protein levels in cell or tissue lysates

• Immunoprecipitation (IP): For isolating XRS2 and its interacting proteins

• Immunofluorescence (IF): For visualizing the subcellular localization of XRS2

• Enzyme-linked immunosorbent assay (ELISA): For quantitative measurement of XRS2

For optimal results, researchers should select antibodies validated for their specific application and experimental system, as detection efficiency may vary between applications.

How do I select the appropriate XRS2 antibody format for my experiment?

The selection of XRS2 antibody format depends on your experimental design:

• Non-conjugated antibodies: Best for flexibility in detection methods

• HRP-conjugated: Ideal for direct detection in western blotting without secondary antibodies

• Fluorophore-conjugated (FITC, PE, Alexa Fluor): Optimal for direct detection in immunofluorescence and flow cytometry

• Agarose-conjugated: Most suitable for immunoprecipitation experiments

When designing experiments, consider factors such as detection sensitivity requirements, available imaging equipment, and whether multiplexing with other antibodies is needed.

What controls should I include when using XRS2 antibodies?

Proper controls are critical for interpreting results with XRS2 antibodies:

• Negative control: Include samples from XRS2 knockout/null mutants to confirm antibody specificity

• Loading control: Use housekeeping proteins (e.g., actin, GAPDH) for western blotting

• Isotype control: Include an irrelevant antibody of the same isotype (IgG2a κ for XRS2 Antibody F-4) to identify non-specific binding

• Positive control: Include samples known to express XRS2 (e.g., wild-type cells)

Additional validation may include peptide competition assays or using multiple antibodies targeting different epitopes of XRS2.

How can I distinguish between functional domains of XRS2 using antibody-based approaches?

To differentiate between functional domains of XRS2, researchers can employ several antibody-based strategies:

• Domain-specific antibodies: Use antibodies targeting specific regions (N-terminal FHA domain, C-terminal Mre11-binding region, or Tel1-interaction domain)

• Truncation mutant analysis: Combine antibody detection with expression of truncated XRS2 variants (such as xrs2-84M, xrs2-228M, xrs2-630) to map domain functionality

• Protein interaction studies: Perform co-immunoprecipitation with anti-XRS2 antibodies followed by western blotting for interaction partners (e.g., Mre11, Tel1) to assess domain-specific interactions

For example, co-immunoprecipitation experiments have revealed that the C-terminal region from amino acids 630-664 of XRS2, particularly lysine residues 641 and 645, is critical for Mre11 binding .

How do I troubleshoot low signal issues when using XRS2 antibodies in western blotting?

When experiencing low signal with XRS2 antibodies in western blotting:

• Check protein expression levels: Some XRS2 mutants (e.g., xrs2-84M, xrs2-228M) show approximately fivefold lower protein levels than wild-type XRS2

• Optimize antibody concentration: Titrate primary antibody concentration (typical starting range: 1:500-1:2000)

• Increase protein loading: Load more total protein if XRS2 is expressed at low levels

• Enhance detection sensitivity: Use signal enhancement systems (e.g., enhanced chemiluminescence)

• Consider protein phosphorylation status: XRS2 exhibits heterogeneous mobility on gels due to phosphorylation, which may affect antibody recognition

Additionally, verify that your lysis buffer preserves protein integrity, as some XRS2 mutants may form less stable complexes with other proteins.

What approaches can I use to study XRS2 protein interactions in vivo and in vitro?

To examine XRS2 protein interactions:

In vivo approaches:

• Co-immunoprecipitation: Use anti-XRS2 antibodies to pull down XRS2 and its interacting partners (e.g., Mre11, Rad50)

• Proximity ligation assay: Visualize protein-protein interactions in situ with fluorescent signal generation

• FRET/BRET analysis: Monitor real-time protein interactions using fluorescent/bioluminescent tags

In vitro approaches:

• Yeast two-hybrid analysis: Quantify interactions between XRS2 and other proteins (e.g., Mre11)

• Pull-down assays: Use purified proteins to verify direct interactions

• Surface plasmon resonance: Measure binding kinetics and affinity

Research has shown that the interaction between XRS2 and Mre11 can be quantified using β-galactosidase activity in yeast two-hybrid assays, with mutations affecting interaction strength .

How do mutations in different XRS2 domains affect its function in DNA repair and recombination?

XRS2 mutations exhibit domain-specific effects on DNA repair and recombination:

This data demonstrates that the Mre11-binding domain (residues 630-664) is essential for all XRS2 functions, while the Tel1-binding domain primarily affects telomere maintenance. The N-terminal domain, despite containing the conserved FHA domain, is less critical for DNA repair but influences meiotic recombination when protein levels are reduced .

What are the optimal conditions for immunoprecipitation using XRS2 antibodies?

For successful immunoprecipitation with XRS2 antibodies:

• Cell lysis: Use gentle lysis buffers (e.g., 50mM Tris-HCl pH 7.5, 150mM NaCl, 1% NP-40) that preserve protein-protein interactions

• Antibody selection: Choose agarose-conjugated antibodies (e.g., XRS2 Antibody F-4 AC) or couple non-conjugated antibodies to protein A/G beads

• Antibody amount: Typically use 2-5μg antibody per 500μg-1mg of total protein

• Incubation conditions: Perform binding at 4°C overnight with gentle rotation

• Wash stringency: Balance between removing non-specific interactions and preserving specific complexes

• Elution method: Use gentle elution for functional studies or harsh conditions (SDS buffer) for maximum recovery

Co-immunoprecipitation experiments have successfully identified the interaction between XRS2 and Mre11, demonstrating that specific mutations (xrs2-630, xrs2-AA) abolish this interaction .

How can I quantitatively assess XRS2 protein expression levels in different mutants?

To quantitatively measure XRS2 protein expression:

• Western blotting: Use anti-XRS2 antibodies with appropriate controls

• Densitometry analysis: Normalize XRS2 band intensity to loading controls

• Standard curves: Include dilution series of purified protein or wild-type lysate

• ELISA: Develop quantitative ELISA using XRS2 antibodies for higher throughput

• Mass spectrometry: Employ targeted proteomics approaches (MRM/PRM) for absolute quantification

When analyzing XRS2 mutants, consider that some may have reduced expression levels. For example, the xrs2-84M and xrs2-228M mutants show approximately five-fold lower protein levels compared to wild-type, requiring adjustments in experimental design and interpretation .

What techniques can I use to analyze meiotic DSB formation and repair in XRS2 mutants?

To analyze meiotic DSB formation and repair in XRS2 mutants:

• Southern blotting: Monitor DSB formation and resolution at specific hot spots (e.g., HIS4-LEU2)

• Return-to-growth assays: Measure recombination frequency using prototroph formation (e.g., His+, Arg+)

• Tetrad analysis: Assess spore viability and recombination outcomes

• ChIP assays: Examine recruitment of repair proteins to DSB sites

• Pulsed-field gel electrophoresis: Analyze chromosome integrity during meiosis

Experimental design should include time course analysis, as some mutants (e.g., xrs2-228M) show delayed kinetics of DSB repair and crossover product formation. Wild-type strains typically show maximum DSB levels after 3 hours in sporulation medium, with crossovers appearing after 4 hours .

How do I differentiate between direct and indirect effects of XRS2 mutations on cellular phenotypes?

To distinguish direct from indirect effects of XRS2 mutations:

• Domain-specific mutations: Compare mutations in different functional domains

• Complementation experiments: Restore wild-type phenotype by expressing intact XRS2

• Protein overexpression: Test if overexpression of mutant proteins rescues phenotypes

• Epistasis analysis: Combine XRS2 mutations with mutations in interacting proteins

• Conditional alleles: Use temperature-sensitive or inducible systems to control timing of XRS2 function

How should I interpret conflicting results between different assays when studying XRS2 function?

When faced with conflicting results across different assays:

• Consider protein levels: Some XRS2 mutants show reduced expression, affecting interpretation

• Examine interaction stability: Mutations may weaken, not eliminate, protein interactions

• Evaluate assay sensitivity: Co-immunoprecipitation and two-hybrid assays have different sensitivity thresholds

• Assess physiological relevance: In vitro results may not perfectly match in vivo observations

• Check cellular context: Different cell types or conditions may influence XRS2 function

For instance, the xrs2-84M mutant shows reduced Mre11 interaction in co-immunoprecipitation experiments but maintains significant interaction in two-hybrid analysis. This discrepancy may be explained by differences in protein expression levels or assay sensitivity .

What statistical approaches are most appropriate for analyzing XRS2-related experimental data?

For statistical analysis of XRS2-related experiments:

• For survival assays: Use log-rank tests or similar survival analysis methods

• For recombination frequencies: Apply chi-square tests for categorical outcomes

• For protein interaction quantification: Use t-tests or ANOVA for β-galactosidase activity comparisons

• For time-course experiments: Employ repeated measures ANOVA or mixed-effects models

• For microscopy data: Consider distribution-appropriate tests (normal vs. non-parametric)

When comparing multiple mutants, correct for multiple testing using methods such as Bonferroni or false discovery rate approaches. Report both statistical significance and effect sizes to provide complete information .

How can I determine if observed phenotypes in XRS2 mutants are due to direct loss of function or secondary effects?

To determine the nature of phenotypes in XRS2 mutants:

Research with the xrs2-630 and xrs2-AA mutants demonstrates that loss of Mre11 binding causes pleiotropic defects in multiple pathways, indicating that MRX complex formation is a prerequisite for all XRS2 functions. In contrast, the xrs2-664 mutant specifically affects telomere maintenance while preserving other functions, suggesting a separation of functions at the C-terminus .

What are the key considerations when comparing XRS2 function across different species and model systems?

When comparing XRS2 across species and model systems:

• Recognize homologs: XRS2 (yeast) corresponds to NBS1/Nibrin in humans, not XRCC2

• Consider domain conservation: The FHA domain is conserved, but other regions show divergence

• Examine functional conservation: Core functions in DNA repair are conserved, but regulatory mechanisms may differ

• Evaluate model-specific differences: Yeast and mammalian systems have distinct chromatin organization and cell cycle regulation

• Assess technological limitations: Different detection methods may have varying sensitivity across systems

While the N-terminal FHA domain is conserved between yeast XRS2 and human NBS1, the data suggest that, unlike in humans, this domain is not essential for major functions of the MRX complex in yeast. This highlights the importance of careful cross-species comparisons when translating findings between model systems .